Alzheimer’s Memory Center (AMC) was founded in 2008 by Mohammad Reza Bolouri, MD. Dr. Bolouri is a board certified Neurologist with over 20 years of clinical research experience. He has completed over 120 Phase II – IV clinical trials. Although our primary research focus is ALZHEIMER’S DISEASE, we have experience in many therapeutic areas including:
|
|
AMC is experienced in the following types of clinical trials:
- Pharmacokinetic/Pharmacodynamic
- Dose Ranging Studies
- Drug-Drug Interaction Studies
- Safety & Efficacy
- Proof of Concept Studies
- Outpatient Studies
AMC has a database of more than 2,000 individuals. This includes private patients, individuals who have participated in clinical trials or those who have expressed an interest in clinical trials. In addition to our database Dr. Bolouri is well respected in the local community and has access to a network of physicians to exchange ideas and enhance best practices in patient recruitment. We are conveniently located in the heart of Charlotte NC. This central location is minutes away from several major hospitals with easy access to multiple freeways and an international airport. Our facility includes:
- A dedicated research facility.
- 5 examination rooms.
- A psychometrics evaluation room.
- On-site Clia Certified Laboratory Services.
- A monitor room with wireless access.
- Secured investigational drug storage facilities.
- Access to a large conference room.
Dr. Bolouri has partnered with the following pharmaceutical sponsors:
- Abbott Laboratories
- Astra
- Astra-Merck
- Athena Neurosciences
- Baker-Norton Pharmaceuticals
- Battelle
- Bayer
- Biovail
- Boehringer Ingelheim
- Bristol Myers Squibb
- CIBA-Geigy Pharmaceuticals
- Eisai
- Eli Lilly and Company
- Forest Laboratories
- Glaxo INC.
- Hoechst-Roussel
- Hoffman-La Roche
- Janssen Research Foundation
- Lundbeck
- Marion Merrill Dow
- Merck Research Laboratories
- Merck, Sharp and Dohme
- Merz
- Miles INC.
- Novartis
- Organon Akzo Nobel
- Parke-Davis
- Pfizer
- Protodigm
- Sandoz
- Sanofi
- Schwabe
- Sigma-Tau Pharmaceuticals
- Smithkline-Beecham
- Somerset
- Takeda
- Toyama
- University of California
- Upjohn Laboratories
- Warner Lambert Parke Davis
- Wyeth Ayerst
Research Experience
- The efficacy and safety of Depakote in subjects with migraines
- An open label study for the safety of long term Tiagabine HCl in subjects with epilepsy
- A randomized, double blind, placebo controlled, comparision of the study drug to placebo in subjects with painful diabetic polyneuropathy
- A randomized, placebo-controlled, double-blind, 16 week study of the safety and tolerability of the study medication in patients with mild to moderate Alzheiner’s disease
- A placebo-controlled, dose ranging safety and tolerability pilot study of remacemide hydrochloride in subjects with probable Alzheimer’s disease
- A double blind randomized, placebo controlled study to access the efficacy and tolerability of Tizanidine tablets for inpatients suffering from spasticity due to Multiple Sclerosis
- An open lable long tern study to evaluate the safety of Tizandine tablets in patients sufferinf from spasticity due to Multiple Sclerosis
- A double-blind, placebo controlled study of Alzene in Alzehimer’s patients with mild to moderatly severe cognative decline
- Delay in nursing home placement of Alzheimer’s diesase patietns treated with the Aricept Clinical Program
- Multicenter, open label study of the safety and tolerability of metrifonate in patients with probable Alzehimer’s disease
- Double-blind, placebo-controlled trial to evelauate the safety and efficacy of fixed-dose metifonate tablets in patients with probable Alzehimer’s disease
- Trial to evaluate the safety and efficacy of a fixed-dose metrifonate tablet comparing a loading dose phase and no loading dose phase vs placebo in patients with probable Alzheimer’s disease
- Open-label study of the safety and tolerability of metrifonate in patietns with probable Alzheimer’s diesease.
- Long-term treatment with metrifonate for patients with probable Alzhemier’s diesase.
- A double-blind, active controlled trial to evaluate the safety of switching patients with mild to moderate Alzehimer’s disease from Donepezil to Metrifonate
- Study of the efficacy, safety and tolerability 30mg anf 90mg Busprione hydrochloride extended relaese compared to placebo in patients with generalized Anxeity Disorder
- Efficacy, safety and tolerabiltiy of up to 90mg Busprine hydochloride Extended Release in patients with Generalized Anxeity Disorder
- Efficacy and safety of 6, 12, 24 and 36 mg tid po and 36mg bid po talsaclidine (free base) for 12 weeks in patients with mild to moderate dementia of Alzheimer’s type
- Long-tern safety and tolerability of oral administration of Talsaclidine 24mg TID in patients with mild to moderate dementia of the Alzheimer type
- Open pilot study of study medication to identify a safe and effective dose range for the treatment of symptoms of Mild Dementia of the Alzheimer type
- A placebo controlled study of the medication in Alzheimer’s type Demented patients
- An open multi-center trial of Nefazodone on the treatment of patients with mood disorders
- Trial of Nefazodone vs placebo in the treatment of elderly depressed outpatients
- Oxiracentam in the treatment of primary degenerative dementia of mild to moderate severity, low dose schedule
- Oxiracentam in the treatment of primary degenerative dementia of mild to moderate severity, high dose schedule
- Oxiracentam in the treatment of multiple infarct dementia mild to moderate severity, low dose schedule
- Evaluation of the safety and efficacy of the study drug in patients with Alzheimer’s disease
- Preliminary study to determine the efficacy and safety of donepezil hydrochloride in patients with persistent mild to moderate memory impairments resulting from a single closed head injury
- Evaluation of the study and efficacy of the study drug in patients with Alzheimer’s disease
- A 24 week placebo controlled evaluation of the efficacy and safety of Donepezil Hydrochloride in patients with dementia associated with cerebrovascular disease
- A 30 week, open-label evaluation of Donepezil Hydrochloride in patients in Dementia associated with cerebrovascular disease
- An open-label, multi-center, extended evaluation of the safety and efficacy of the study medication in patients with Alzheimer’s disease
- 54-week evaluation of the effects of donepezil hydrochloride on function outcomes in patients with Alzheimer’s disease with a stage crossover to open-label donpezil hydrochloride treatment
- open-label trial evaluating the safety and efficacy of donepezil hydrochloride in patients of Alzheimer’s disease
- A 24-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donpezil hydrochloride in patients with severe Alzheimer’s disease followed by a 12 week open label extension period
- A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of donpezil hydrochloride in patients with early Alzheimer’s disease
- Safety and efficacy of Olanzapine of cognitive symptoms in subjects with mild to moderate Alzheimer’s disease
- Safety and efficacy of the Xanolmeline Transdermal Therapeutic System in patients with mild to moderate Alzheimer’s disease
- Open label extension of Xanomeline registration phase efficacy trials using Xanolmeline Transdermal Therapeutic System
- Fluoxetine versus sertraline and paroxetine in major depression: comparison of discontinuation-emergent signs and symptoms
- Olanzapine versus risperidone and placebo in the treatment of Psychosis and Associated Behavioral Disturbances in patients with dementia
- R-fluoxetine versus placebo in the treatment of major depression
- the study of Olanzapine and fluoxetine in combination for treatment resistant depression without psychotic features
- The efficacy and safety of long term administration of controlled-release oral Physostigmine in Alzheimer’s disease and senile dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with moderate to severe dementia of the Alzheimer’s type
- A randomized, titration with long-term open-label evaluation of the safety and efficacy of Memantine in patients with moderate to severs dementia of the Alzheimer’s type
- A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of Mematine in patients with mild to moderate dementia of the Alzheimer’s type
- Evaluation of a combined regimen of subcutaneous and oral study medication in the prevention of Migraine recurrence
- A controlled study of Ondansetron in the treatment of Alzheimer’s type dementia
- A controlled study of Ondansetron in the treatment of primary degenerative dementia of the Alzheimer’s type
- A double-blind evaluation of the safety and efficacy of oral ondansetreon in the treatment of patients with panic disorder
- A long term tolerance and safety study of study drug in patients with Alzheimer’s disease
- A multi-center, 30 week, double-blind, parallel group safety, tolerance and efficacy comparison of placebo and Mentane in outpatients with Alzheimer’s disease
- A double-blind placebo controlled, parallel group, dose range finding study of Lazabemide in patients with Alzheimer’s disease
- An open label treatment extension study of Lazabemide in patients with Alzheimer’s disease completing protocol
- Evaluation of the safety and efficacy of fixed doses of sabeluzone vs. placebo in the treatment of patients diagnosed with dementia of the Alzheimer’s type
- Clinical evaluation of efficacy and safety of Sabeluzole in the treatment of Alzheimer’s disease
- Efficacy, tolerability and safety of Glalamtamine in the treatment of Alzheimer’s disease
- Long-term safety and efficacy of Glalamtamine in the treatment of Alzheimer’s disease
- Glalamtamine in the treatment of Alzheimer’s disease: flexible dose range trial
- Safety and efficacy of Glalamtamine during withdrawal in the treatment of Alzheimer’s disease
- Open-label use of synthetic Glalamtamine in the treatment of Alzheimer’s disease
- A randomized, placebo-controlled trial to evaluate the efficacy and safety of Glalamtamine in patients with minimal cognitive impairment clinically at risk for development of probable Alzheimer’s disease
